Physician profile
Stephen M John
NPI 1275763062
$3,761.72
in general payments reported to CMS, 2019-2025
20 companies · $546 in 2025
The $546 reported for 2025 was more than what 79% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,825 · 2020: $212 · 2021: $454 · 2022: $180 · 2023: $161 · 2024: $383 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,090.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,090.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,346.24 | 2019-2025 | Tecnis Simplicity |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $383.33 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $272.45 | 2019-2022 | |
| Glaukos Corporation | $188.37 | 2024-2025 | Ce-Marked Kxla System, Idosetr |
| Alcon Vision LLC | $188.18 | 2021-2025 | Clareon, Tryptyr |
| Bausch & Lomb Americas INC. | $183.82 | 2022-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Johnson & Johnson Vision Care, INC. | $157.99 | 2022-2025 | Acuvue |
| Dompe US, INC. | $156.56 | 2024-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $139.34 | 2021-2023 | |
| Eyevance Pharmaceuticals LLC | $134.83 | 2021 | |
| Allergan, INC. | $130.81 | 2020-2021 | |
| Oyster Point Pharma, INC. | $119.12 | 2022-2024 | Tyrvaya |
| Abbvie INC. | $90.16 | 2023-2025 | |
| Tarsus Pharmaceuticals, INC. | $65.16 | 2024 | Xdemvy |
| Rxsight INC | $51.42 | 2022-2024 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $45.09 | 2024 | Tepezza |
| Shire North American Group INC | $37.84 | 2019 | |
| Quidel Corporation | $32.66 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Astellas Pharma US INC | $18.95 | 2023 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.